Analysts Anticipate Krystal Biotech, Inc. (NASDAQ:KRYS) to Announce -$0.55 EPS

Equities research analysts expect that Krystal Biotech, Inc. (NASDAQ:KRYS) will report earnings per share of ($0.55) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Krystal Biotech’s earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.64). Krystal Biotech reported earnings of ($0.31) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 77.4%. The business is scheduled to report its next quarterly earnings report on Tuesday, March 9th.

According to Zacks, analysts expect that Krystal Biotech will report full year earnings of ($1.74) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.68). For the next financial year, analysts forecast that the company will report earnings of ($2.53) per share, with EPS estimates ranging from ($2.97) to ($2.05). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Krystal Biotech.

A number of equities analysts have weighed in on the stock. HC Wainwright increased their price target on shares of Krystal Biotech from $68.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, January 8th. Jonestrading started coverage on shares of Krystal Biotech in a report on Tuesday, February 9th. They set a “buy” rating and a $97.00 price objective for the company. Zacks Investment Research raised shares of Krystal Biotech from a “sell” rating to a “hold” rating in a report on Wednesday, January 13th. Finally, B. Riley reiterated a “buy” rating and set a $100.00 price target on shares of Krystal Biotech in a research report on Wednesday, November 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $91.17.

Shares of KRYS stock traded down $2.92 during trading hours on Tuesday, hitting $74.01. The company’s stock had a trading volume of 2,753 shares, compared to its average volume of 167,778. The business has a fifty day moving average of $69.25 and a 200-day moving average of $53.24. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -51.98 and a beta of 1.20. Krystal Biotech has a twelve month low of $33.08 and a twelve month high of $79.00.

A number of institutional investors have recently made changes to their positions in KRYS. Victory Capital Management Inc. boosted its position in Krystal Biotech by 88.5% during the third quarter. Victory Capital Management Inc. now owns 524,144 shares of the company’s stock worth $22,565,000 after purchasing an additional 246,047 shares during the period. BlackRock Inc. boosted its position in Krystal Biotech by 17.6% during the fourth quarter. BlackRock Inc. now owns 1,407,348 shares of the company’s stock worth $84,441,000 after purchasing an additional 210,428 shares during the period. FIL Ltd boosted its position in Krystal Biotech by 295.8% during the fourth quarter. FIL Ltd now owns 241,326 shares of the company’s stock worth $14,480,000 after purchasing an additional 180,350 shares during the period. JPMorgan Chase & Co. boosted its position in Krystal Biotech by 178.8% during the fourth quarter. JPMorgan Chase & Co. now owns 239,312 shares of the company’s stock worth $14,359,000 after purchasing an additional 153,490 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Krystal Biotech by 23.1% during the third quarter. Point72 Asset Management L.P. now owns 663,889 shares of the company’s stock worth $28,580,000 after purchasing an additional 124,647 shares during the period. 73.05% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa.

Read More: Basic Economics

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.